Tempus AI Target of Unusually Large Options Trading (NASDAQ:TEM)

Tempus AI, Inc. (NASDAQ:TEM) saw some unusual options trading on Thursday. Stock traders acquired 11,239 call options on the stock. This represents an increase of 120% compared to the typical daily volume of 5,113 call options.

Tempus AI Stock Performance

NASDAQ:TEM opened at $41.00 on Friday. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI has a 12-month low of $22.89 and a 12-month high of $79.49. The business has a fifty day moving average of $52.64.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Piper Sandler reaffirmed a “neutral” rating and issued a $70.00 price target (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and boosted their target price for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Bank of America increased their price target on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday. Guggenheim initiated coverage on Tempus AI in a report on Monday, December 9th. They set a “buy” rating and a $74.00 price objective on the stock. Finally, Loop Capital lifted their target price on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $56.00.

Insider Activity

In other Tempus AI news, major shareholder Bradley A. Keywell sold 395,800 shares of Tempus AI stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the transaction, the insider now directly owns 16,164,449 shares of the company’s stock, valued at approximately $694,263,084.55. This trade represents a 2.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David R. Epstein sold 620 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total transaction of $25,922.20. Following the sale, the director now directly owns 27,894 shares of the company’s stock, valued at approximately $1,166,248.14. The trade was a 2.17 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 650,949 shares of company stock worth $27,821,944.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TEM. EFG Asset Management North America Corp. bought a new stake in shares of Tempus AI in the 2nd quarter valued at $1,333,000. ARK Investment Management LLC bought a new stake in Tempus AI during the 2nd quarter worth approximately $18,294,000. Northwestern University acquired a new stake in Tempus AI during the 2nd quarter worth approximately $491,000. Alphabet Inc. bought a new position in Tempus AI in the second quarter valued at approximately $54,289,000. Finally, Pier Capital LLC acquired a new position in shares of Tempus AI in the second quarter valued at approximately $2,301,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.